FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)

Study ID
NCT01328171

Study type
Interventional

Study phase
Phase 2

Study status
Completed

Trial Acronym

VOLFI

Trial Summary

The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer of RAS wildtype. The patients will be treated in two therapy groups: Experimental arm A: Chemotherapy with FOLFOXIRI + panitumumab Standard arm B: Chemotherapy with FOLFOXIRI

More informations

Trial Starting Date

Apr 30,2011

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit